作者: JC Becker , C Müller-Tidow , H Serve , W Domschke , T Pohle
关键词:
摘要: Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated gastric cancer being prime targets a tailored therapy. Only preliminary data exist, however, on use currently clinically available drugs trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, imatinib setting cancer. Preclinical suggest potential benefit their use, especially combination with “conventional” cytostatic This review summarizes current knowledge about therapy well new approaches to optimize treatment success.